Tibet Rhodiola Pharmaceutical Holding Co.,Ltd.’s Net Profit Dropped 11.7% in First Half of 2022

Tibet Rhodiola Pharmaceutical Holding Co.,Ltd. (西藏诺迪康药业股份有限公司) (600211.SH) reported a net profit of 265.2 million yuan in the first half of 2022, down 11.7% year-on-year.

Meanwhile, the company posted 1.3 billion yuan in revenue, up 29.4% year-on-year.

At the end of the reporting period, it had 4 billion yuan in total assets and 1.2 billion yuan in total liabilities, with a liability-to-asset ratio of 28.8%.